Latest News and Press Releases
Want to stay updated on the latest news?
-
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.
-
Masonic Cancer Center, University of Minnesota to Present Human Data Readout for HCW9218 Phase 1 Study at SITC 2023
-
MIRAMAR, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
-
MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
-
MIRAMAR, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
-
MIRAMAR, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing...
-
Provides funding for buildout of new headquarters and manufacturing facility Capital requirements now funded into 2025 MIRAMAR, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the...
-
Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage, lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., April 13, 2023 (GLOBE...
-
HCW Biologics Published a Pivotal Scientific Paper in Aging Cell Subcutaneous Administration of HCW9218 Systemically Reduces Senescent Cells and Alleviates Senescence-Associated Secretory Phenotype...
-
MIRAMAR, Fla., March 28, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...